DNA Methylation and the Cancer Epigenome Biological and Translations Implications

Video   Jan 01, 2014

 

About the Speaker

Stephen B. Baylin, M.D., is deputy director of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Virginia and D.K. Ludwig professor of oncology and medicine. He is chief of the Cancer Biology Division and associate director for research of the center.


Abstract

Genome-wide mapping studies are dramatically contributing to remarkable increases in our understanding of epigenetic abnormalities in cancer.  Abnormal DNA methylation, both losses and gains, and key associated chromatin changes may largely affect  distinct  genomic  regions which contain nuclear lamin associated,  late replicating DNA , enriched for  low transcription, developmental, genes  with promoter region, “bivalent” chromatin .  Such chromatin, in embryonic and adult stem cells, is essential for maintenance of the stem cell state.  Furthermore, in multiple tumor types, frequent mutations are being found in genes which control normal epigenomes.  While the phenotypic consequences of these largely remain to be dissected, mutations in the IDH1 and 2 genes, and in the Tet family of proteins which trigger steps for active DNA de-methylation, are now linked to DNA methylation and chromatin alterations associated with abnormal gene silencing.  Importantly, multiple of the above epigenetic abnormalities are being found in cancer-risk states which involve chronic inflammation and attendant increases in reactive oxygen species (ROS).  Finally, all of the above biology has exciting translational implications for the concepts of “epigenetic therapy” for cancer and molecular signatures which can guide such treatments and also be useful for cancer diagnosis and staging.

 
 
 
 

Recommended Videos

Tools for Gene Function Analysis

Video

LabTube Meets Catherine Goh, Head of Product Development and Marketing, SiTools Biotech GmbH.

WATCH NOW

The Evolution of PCR

Video

Launching the first FDA-approved PCR test in 1993, Roche Molecular Diagnostics has not only defined and refined PCR, but it has remained the clear leader of this technology.

WATCH NOW

RNAi, a Promising Potential New Class of Medicines

Video

RNAi is a novel and innovative approach to specifically target and silence any gene involved in the cause or pathway of disease.

WATCH NOW

 

Comments | 0 ADD COMMENT

Like what you just watched? You can find similar content on the communities below.

Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE